Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jamie V. Shaw
Observed names:
J. Shaw,
Jamie Shaw,
Jamie Shaw2,
Shaw, Jamie,
Shaw, Jamie V.
Institution:
Merck Healthcare KGaA, Darmstadt (Germany)
Observed institutions:
Merck KGaA, Darmstadt (Germany),
EMD Serono, Inc. (United States),
Merck Healthcare KGaA, Darmstadt (Germany)
ORCID:
0000-0001-5131-7639
Observed ORCID:
0000-0001-5131-7639
OpenAlex ID:
A5045381285
Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8
2021
·
Andreas Port
, Jamie V. Shaw
, et al.
·
Pharmacology Research & Perspectives
·
58
PDF
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
2021
·
Apostolia-Maria Tsimberidou
, Jamie V. Shaw
, et al.
·
Journal of Hematology & Oncology
·
32
PDF
Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study
2024
·
Xavier Montalban
, Karolina Piasecka-Stryczynska
, et al.
·
Multiple Sclerosis Journal
·
28
Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial
2024
·
Lena Klopp‐Schulze
, Sathej Gopalakrishnan
, et al.
·
Clinical Pharmacology & Therapeutics
·
25
AKT inhibition in the central nervous system induces signaling defects resulting in psychiatric symptomatology
2022
·
Apostolia-Maria Tsimberidou
, Antonis Skliris
, et al.
·
Cell & Bioscience
·
23
PDF
Applying Modeling and Simulations for Rational Dose Selection of Novel Toll‐Like Receptor 7/8 Inhibitor Enpatoran for Indications of High Medical Need
2022
·
Lena Klopp‐Schulze
, Jamie V. Shaw
, et al.
·
Clinical Pharmacology & Therapeutics
·
21
PDF
Enpatoran in COVID ‐19 pneumonia: Safety and efficacy results from a phase II randomized trial
2023
·
John E. McKinnon
, Joel Santiaguel
, et al.
·
Clinical and Translational Science
·
12
PDF
Toll-like receptor 8 activation induces a neutrophil inflammatory phenotype: therapeutic implications for the utility of toll-like receptor 8 inhibition
2025
·
Angelika Schmidt
, Matthew Coughlin
, et al.
·
Journal of Leukocyte Biology
·
6
PDF
The Novel Aurora Kinase Inhibitor AS703569 Shows Potent Anti-Tumor Activity in Acute Myeloid Leukemia (AML).
2007
·
Samantha Sarno
, Jamie Shaw
, et al.
·
Blood
·
6
P135 A phase I, first-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of M5049, a dual antagonist of TLR7/8, in healthy subjects
2020
·
Andreas Port
, Lena Klopp-Schulze
, et al.
·
Lupus Science & Medicine
·
2
PDF
Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities.
2018
·
Apostolia Maria Tsimberidou
, Claire F. Verschraegen
, et al.
·
Journal of Clinical Oncology
·
2
Pharmacodynamic (PD) biomarkers for the p70S6K/Akt inhibitor, M2698: Translation from animal to human and relevance to dose selection
2017
·
W. Xiong
, H. Tian
, et al.
·
Annals of Oncology
·
2
PDF
Abstract LB-456: Evaluation of brain pharmacokinetics as a potential differentiation factor for the MEK inhibitors, MSC2015103 and pimasertib
2012
·
Jamie V. Shaw
, Hong Zhang
, et al.
·
Cancer Research
·
2
Phase I dose escalation study of M2698, a p70S6K/AKT inhibitor, in patients with advanced cancer
2017
·
A.M. Tsimberidou
, C. Verschraegen
, et al.
·
Annals of Oncology
PDF
Abstract 2603: Combination activity of the MEK inhibitor Pimasertib and the hypoxia-activated prodrug TH-302 in pancreatic and biliary tract tumor xenograft models
2015
·
Jianguo Ma
, Sakeena Syed
, et al.
·
Cancer Research
Abstract LB-208: Hijacking the PI3K/mTor and KRas/MEK/ERK signaling pathways with a therapeutic assault results in robust antitumor activity in PI3K/KRas and KRas mutant tumors
2011
·
Loic Vincent1
, Anne Thomas1
, et al.
·
Cancer Research
Show more works
View as search
Works count:
21
Citation count:
219
H-index:
7
I10-index:
7
Year
Topic
Type